Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: B.D. who wrote (19980)	5/4/1998 8:42:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

BD, Actually, the NYTimes article was uploaded on Saturday. CNBC reporting that ENMD closed at $12 and bid is up to $40 so far this morning.

To: B.D. who wrote (19980)	5/4/1998 9:06:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

LGND has a very broad anti-angiogenesis program that targets MMPI's among other things (also selectins). The goal is to cut off blood supply and inhibit formation of new blood vessels by blocking MMPs (matrix metalloproteins). Other companies have similar approaches. Roche recently ended its MMPI program with AGPH and BBIOY has nose dived recently. Actually, the price jump in ENMD this morning is remarkably similar to BBIOY's rise several years ago following CNBC's Joe Kernan's comments (I think that BBIOY went from around $12 to triple digits in one day).

To: B.D. who wrote (19980)	5/4/1998 1:04:00 PM
From: Andreas Helke	Read Replies (3) \| Respond to of 32384

I consider Entremeds angiogenesis inhibitors to be one of the biggest risks for Ligands cancer franchise. Therefore a few months ago I have proposed on this thread to buy a few Entremed shares as a hedge of this risk. So far Entremed goes up much faster than Ligand goes down - the hedge is actually working. I don't think that Endostatin will be in the pharmacy in two years but by then we will know if it works as well in humans as it does in mice. (T. Boehm et. al. - Nature, vol 390, 27. november 1997, pages 404-407) Andreas